Seelos Therapeutics, Inc. (SEEL) Financial Statements (2024 and earlier)

Company Profile

Business Address 300 PARK AVENUE
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15,53378,73415,66210,2613,5796,331
Cash and cash equivalents15,53378,73415,66210,2613,5796,331
Receivables      
Prepaid expense304246    
Other undisclosed current assets6,8374,4811,832835106261
Total current assets:22,67483,46117,49411,0963,6856,592
Noncurrent Assets
Operating lease, right-of-use asset7239  
Property, plant and equipment     3879
Other noncurrent assets     3735
Total noncurrent assets:7239  75114
TOTAL ASSETS:22,74683,50017,49411,0963,7606,706
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,9085,4213,8112,7151,1511,571
Employee-related liabilities   272863
Accounts payable3,6261,6931,88779623558
Accrued liabilities7,2823,7281,9241,919644650
Debt11,8651,0302,431   
Derivative instruments and hedges, liabilities  4241,062963  
Disposal group, including discontinued operation     21 
Deferred revenue and credits12
Other undisclosed current liabilities2,3851,4121257,100  
Total current liabilities:25,1588,2877,42910,7781,1721,583
Noncurrent Liabilities
Long-term debt and lease obligation8,18417,8907,293   
Long-term debt, excluding current maturities8,18417,8907,293   
Liabilities, other than long-term debt 15   16752
Other liabilities     1658
Operating lease, liability 15   
Derivative instruments and hedges, liabilities      694
Other undisclosed noncurrent liabilities   200325  
Total noncurrent liabilities:8,19917,8907,49332516752
Total liabilities:33,35726,17714,92211,1031,1882,335
Equity
Equity, attributable to parent, including:(10,611)57,3232,572(7)2,5724,371
Common stock10710554272815
Additional paid in capital204,026198,42877,68056,027327,773320,343
Retained earnings (accumulated deficit)(214,744)141,210(75,162)(56,061)(325,229)(315,987)
Other undisclosed equity, attributable to parent  (282,420)    
Total equity:(10,611)57,3232,572(7)2,5724,371
TOTAL LIABILITIES AND EQUITY:22,74683,50017,49411,0963,7606,706

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues12111345375 511
Revenue, net511
Net investment income12111345151  
Gross profit:12111345375 511
Operating expenses(70,916)(61,669)(18,759)(30,122)(9,148)(10,675)
Other undisclosed operating loss(121)(113)(45)  (511)
Operating loss:(70,916)(61,669)(18,759)(29,747)(9,148)(10,675)
Nonoperating expense(2,618)(4,379)(342)(21,508)(70)(1,074)
Other nonoperating income (expense)292(517)  177
Interest and debt expense(14)2,387(164)(29) (100)
Loss from continuing operations:(73,548)(63,661)(19,265)(51,284)(9,218)(11,849)
Loss before gain (loss) on sale of properties:(63,661)(19,265)(51,284)(9,218)(11,849)
Net loss:(73,548)(63,661)(19,265)(51,284)(9,218)(11,849)
Other undisclosed net income (loss) attributable to parent14(2,387)16429(24)12,170
Net income (loss) available to common stockholders, basic:(73,534)(66,048)(19,101)(51,255)(9,242)321
Other undisclosed net loss available to common stockholders, diluted      
Net income (loss) available to common stockholders, diluted:(73,534)(66,048)(19,101)(51,255)(9,242)321

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(73,548)(63,661)(19,265)(51,284)(9,218)(11,849)
Comprehensive loss:(73,548)(63,661)(19,265)(51,284)(9,218)(11,849)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(73,548)(63,661)(19,265)(51,284)(9,218)(11,849)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: